Division of Biomedical Sciences, Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, Coventry CV2 2DX, United Kingdom.
University Hospitals Coventry & Warwickshire, Coventry CV2 2DX, United Kingdom.
Eur J Obstet Gynecol Reprod Biol. 2023 Aug;287:8-19. doi: 10.1016/j.ejogrb.2023.05.030. Epub 2023 May 26.
Preservation of reproductive function is a key concern for many premenopausal women with breast cancer, given the known gonadotoxic effects of treatments. The present systematic review aimed to investigate the effectiveness and safety of fertility preservation strategies in pre-menopausal women with breast cancer.
Primary research assessing fertility preservation strategies of any type was identified. Markers of preservation of fertility including return of menstrual function, clinical pregnancy rates and live birth rates were selected as main outcome measures. An additional analysis of safety data was also performed.
Fertility preservation interventions were overall associated with higher fertility outcomes: with a pooled odds ratio 4.14 (95% CI 3.59-4.77) for any kind of fertility preservation intervention. This was seen both for return of menstruation and for clinical pregnancy rate, but not for live birth rates. Fertility preservation was associated with a reduced rate of disease recurrence (OR 0.63 (95% CI 0.49-0.81)), while there was no significant difference in disease free survival (OR 0.88 (95% CI 0.74-1.05)) or in overall survival (OR 0.9 (95% CI 0.74-1.10)) between the fertility preservation group and those who had not undergone fertility preservation.
Fertility preservation is both effective in preserving reproductive function, and safe with regard to disease recurrence, disease free survival and overall survival in premenopausal women with breast cancer.
鉴于治疗对性腺有明显的毒性作用,许多患有乳腺癌的绝经前妇女都非常关注生殖功能的保留。本系统评价旨在研究生育力保护策略在乳腺癌绝经前妇女中的有效性和安全性。
确定了评估任何类型生育力保护策略的主要研究。选择保留生育力的标志物,包括月经功能恢复、临床妊娠率和活产率,作为主要观察指标。还对安全性数据进行了额外分析。
生育力保护干预总体上与更高的生育力结局相关:任何类型的生育力保护干预的合并优势比(OR)为 4.14(95%置信区间[CI]:3.59-4.77)。这既适用于月经恢复,也适用于临床妊娠率,但不适用于活产率。生育力保护与疾病复发率降低相关(OR 0.63(95%CI:0.49-0.81)),而在无疾病生存率(OR 0.88(95%CI:0.74-1.05))或总生存率(OR 0.9(95%CI:0.74-1.10))方面,生育力保护组与未进行生育力保护组之间无显著差异。
生育力保护在保留生殖功能方面既有效,又能降低乳腺癌绝经前妇女的疾病复发率、无病生存率和总生存率。